GFAP and Alzheimer disease: In conclusion, this systematic review and meta-analysis will comprehensively evaluate and synthesize the existing evidence on blood GFAP levels for prognosticating presymptomatic individuals and those with MCI to help advance risk-stratified treatment strategies for early-phase AD.